# Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR

> **NCT05375474** · PHASE4 · UNKNOWN · sponsor: **China National Center for Cardiovascular Diseases** · enrollment: 650 (estimated)

## Conditions studied

- Transcatheter Aortic Valve Replacement
- Antithrombotic Therapy
- Bioprosthetic Valve Thrombosis

## Interventions

- **DRUG:** Oral anticoagulation therapy
- **DRUG:** Single antiplatelet therapy

## Key facts

- **NCT ID:** NCT05375474
- **Lead sponsor:** China National Center for Cardiovascular Diseases
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 650 (ESTIMATED)
- **Last updated:** 2023-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375474, "Antithrombotic Strategy Based on Clinical Events and 4D-CT for Patients After TAVR". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05375474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*